Olanib 50 (Olaparib) 50 mg Capsules
Olanib 50 mg (Olaparib) is a potent PARP inhibitor (poly ADP-ribose polymerase inhibitor) used for targeted cancer therapy.
Manufacturer: Everest Pharmaceuticals. Each pack contains 112 capsules. It works by exploiting DNA repair defects in tumors harboring BRCA mutations, causing synthetic lethality and cancer cell death.
Capsule Formulation Note:
This is the 50 mg capsule version. The dosing regimen involves a high pill burden (number of capsules) compared to the newer tablet formulations.
Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced cancers:
- 🔹 Ovarian Cancer: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- 🔹 Therapy Goal: To maintain remission after response to platinum-based chemotherapy.
Packaging: 50 mg capsules.
⚠️ ADMINISTRATION PROTOCOL (Specific for Capsules):
- Total Daily Dose: 800 mg (400 mg twice daily).
- Per Dose: Take 8 capsules (50 mg each) at once, twice daily.
- Total Pills: 16 capsules per day.
- Timing & Food: Take on an empty stomach. Take at least 1 hour after a meal, and do not eat for 2 hours after taking the capsules.
- Administration: Swallow whole. Do not chew, dissolve, or open the capsules.
- Hypersensitivity to Olaparib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Moderate to severe hepatic or renal impairment.
Common adverse reactions include:
- 🩸 Hematological: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood counts are recommended.
- 📉 Gastrointestinal: Nausea, vomiting (very common), diarrhea, loss of appetite, dysgeusia (taste distortion).
- 🌀 Physical: Fatigue (asthenia), headache, dizziness.
- Patients should be monitored for signs of blood toxicity (pale skin, shortness of breath).
What Customers Say
No reviews yet
Your review can be the first!